Results 241 to 250 of about 56,162 (258)

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Cancer Cell, 2015
Sara C Meyer, Sophia Chiu, Priya Koppikar   +2 more
exaly  

Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor

Bioorganic and Medicinal Chemistry, 2018
Yasushi Amano, Shohei Shirakami, Yasuyuki Higashi   +2 more
exaly  

Jak inhibitor ; possibility and mechanism as a new disease modifying anti-rheumatic drug

Japanese Journal of Clinical Immunology, 2009
Kunihiro Yamaoka, Yoshiya Tanaka
exaly  

The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models

American Journal of Transplantation, 2004
exaly  

Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma

Pediatric Dermatology
Mayuko Yamamoto, Kimiko Nakajima, Aya Takahashi   +2 more
exaly  

JAK inhibitors—Friend or Foe?

The Lancet Rheumatology
openaire   +2 more sources

Topikal JAK Inhibitors

Atıl Avcı, Ragıp Ertaş
openaire   +1 more source

JAK Inhibitors in RA

2017
openaire   +1 more source

Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea

Seminars in Arthritis and Rheumatism
Young-Eun Kim, Ye-Jee Kim, Dae Hyun Jeong   +2 more
exaly  

[JAK inhibitors in rheumatology].

La Revue du praticien, 2022
openaire   +1 more source